Literature DB >> 8044216

Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis.

A Briggs1, M Sculpher, M Buxton.   

Abstract

Given the increased use of economic evaluation to inform decision making in the health service, it is particularly important that the research methods used are critically assessed and, where possible, improved. The systematic handling of uncertainty in economic evaluation is an important area that remains methodologically underdeveloped. With the increased use of the clinical trial as a vehicle for economic evaluation, there has been recent interest in how the statistical methods routinely employed to handle uncertainty in clinical research might be applied to economic evaluation. This paper reviews the types of uncertainty that exist in economic evaluation and argues that some forms of uncertainty are not amenable to statistical methods. Sensitivity analysis is not a single approach but can take a number of different forms. The different types of sensitivity analysis are reviewed, with an indication of their strengths and weaknesses in relation to the different types of uncertainty in economic evaluation.

Mesh:

Year:  1994        PMID: 8044216     DOI: 10.1002/hec.4730030206

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  121 in total

1.  Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma.

Authors:  J Lord; F M Ducharme; R J Stamp; P Littlejohns; R Churchill
Journal:  BMJ       Date:  1999-12-04

2.  An economic model to estimate the relative costs over 20 years of different hip prostheses.

Authors:  K Baxter; G Bevan
Journal:  J Epidemiol Community Health       Date:  1999-09       Impact factor: 3.710

3.  Economics notes: handling uncertainty in economic evaluation.

Authors:  A Briggs
Journal:  BMJ       Date:  1999-07-10

4.  Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.

Authors:  D M Pickin; C J McCabe; L E Ramsay; N Payne; I U Haq; W W Yeo; P R Jackson
Journal:  Heart       Date:  1999-09       Impact factor: 5.994

5.  Cost analysis of nurse telephone consultation in out of hours primary care: evidence from a randomised controlled trial.

Authors:  V Lattimer; F Sassi; S George; M Moore; J Turnbull; M Mullee; H Smith
Journal:  BMJ       Date:  2000-04-15

6.  Measuring the costs and benefits of heart disease monitoring.

Authors:  A Perry; S Capewell; A Walker; J Chalmers; A Redpath; K Major; C E Morrison; N Craig; S Cobbe; W C Smith
Journal:  Heart       Date:  2000-06       Impact factor: 5.994

Review 7.  Socioeconomic evaluation in medicine in Europe. Core economic concepts.

Authors:  K Berger; T D Szucs
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

Review 8.  Benefit valuation in economic evaluation of cancer therapies. A systematic review of the published literature.

Authors:  J Brown; M Sculpher
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

9.  Randomized controlled trial and economic evaluation.

Authors:  S Jain; N K Arora
Journal:  Indian J Pediatr       Date:  2000-05       Impact factor: 1.967

10.  Health economic evaluation.

Authors:  A Shiell; C Donaldson; C Mitton; G Currie
Journal:  J Epidemiol Community Health       Date:  2002-02       Impact factor: 3.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.